Author: Gerald Ng

Gerald Ng is the current chief editor for Medical Channel Asia. Writing has always been his first love and he has more than a decade of journalism experience after falling in love with reading the newspapers daily growing up in Singapore. His works and interviews have appeared in various media publications including Yahoo!, Straits Times and Channel NewsAsia.

Collagen, a protein naturally produced by the body, is essential for maintaining skin elasticity, hydration, and strength. Various foods and beverages infused with collagen, such as instant noodles, bubble tea, and bird nest, have recently entered the market, claiming to enhance skin suppleness. But do these products deliver on their promises? Here’s a closer look from a health perspective.

Read More

The World Health Organisation (WHO) recently revealed alarming findings about using baby and talcum powder. According to their latest study, the use of these products may increase the risk of cancer in children, sparking concern among parents and the public. Subsequently, Indonesia’s Minister of Health, Budi Gunadi Sadikin, has responded. He is taking the findings seriously and will consider action related to talcum powder. Cancer Risk from Talcum Powder A global WHO study found that exposure to talc, an active ingredient commonly used in cosmetics such as baby powder and loose powder, may increase the risk of cancer in children.…

Read More

Hydrolysed collagen, a popular supplement, is touted for its benefits to skin, joints, and overall health. But does it really work? This article delves into the medical perspective on hydrolysed collagen, examining its efficacy and potential health benefits based on scientific evidence.

Read More

The Department of Health-Center for Health Development in Bicol (DOH CHD-5) announced a 92% treatment success rate for tuberculosis (TB) cases for Q1 2024. This achievement was highlighted during the “Kapihan sa Bagong Pilipinas” briefing held at the Bicol Medical Center in Naga City. This success is indicative of the region’s robust health initiatives and effective implementation of TB treatment protocols. 

Read More

Roche announced today that Tecentriq® SC (atezolizumab) has been approved by the Singapore Health Sciences Authority (HSA) for all indications in which the intravenous (IV) formulation of Tecentriq has been previously approved, including certain types of lung, breast and liver cancer.4 Tecentriq SC is Roche’s fourth subcutaneous cancer therapy,5-7 and the world’s first injectable anti-PD-(L)1 cancer immunotherapy.

Read More

The National University Hospital (NUH) has launched the National University Centre for Trauma. This centre focuses on comprehensive trauma care and outreach to vulnerable groups, including children, older adults, and migrant workers. The initiative aims to enhance safety and prevent trauma across Singapore.

Read More